Cancer, the word itself is enough to make you anxious and scare you. It’s very important to start checking it at a right time. There are so many companies these days that are working in the cancer field. They develop and produce drugs and different advanced technologies for the cancer treatment. Mirta Biotech is a company that works in fighting this life-threatening disease.
About the company
Mitra Biotech is a biotech company that develops and provides technologies that personalize cancer treatment. Founded in 2010 by Mallik Sundaram, Pradip Majumder, the company is headquartered in Boston. The company also maintains a significant research and laboratory presence in Bangalore. The company’s team includes a team of researchers, scientists, and medical commercialisation professionals. Some of the India’s leading cancer care hospitals like Apollo Hospital-Delhi, Fortis Hospital-Delhi and Healthcare Global Group of Hospitals.
Mitra Biotech has raised $27.4 million in a Series B round of financing led by Sequoia India and Sands Capital Ventures with participation from U.S.-based RA Capital Management and the firm’s existing investors Accel Partners and Tata Capital Innovations Fund. “Accel is proud to continue our investment and active involvement with MitraWe also welcome our new investment partners and look forward to working with them to accomplish Mitra’s long-term clinical and commercial goals. ,” said Mahendran Balachandran, Partner at Accel and Mitra Board member, in a business-standard.com report. The same report says,”Sequoia is pleased to join Mitra in their mission to have cancer patients receive treatments with the highest likelihood of success at the time when they can be most impactful, ” said Anjana Sasidharan, Sequoia Principal and one of the Mitra Board member. “CANScript can also help patients avoid the side effects and costs of ineffective treatments.”
“These new funds will allow us to enhance our technology and engage in new studies to further demonstrate CANScript’s clinical utility. We will also move forward with our commercial efforts in the United States, as well as emerging and other key markets. We are excited to have such distinguished new investors join us in our efforts to personalise therapy selection for cancer patients around the world. We also appreciate the continued support from our ongoing investors and wish to thank our existing investors,” said Mallikarjun Sundaram, in a report by business-standard.com. CANScript is used for therapies for patients and to speed drug development.